Tyra Biosciences, Inc. 8-K

What Happened

• Tyra Biosciences, Inc. (TYRA) filed a Current Report on Form 8-K on March 2, 2026 announcing its financial results for the year ended December 31, 2025.
• The company issued a press release with the results, which is attached to the 8-K as Exhibit 99.1. The filing was signed by CFO Alan Fuhrman.

Key Details

• Filing date: March 2, 2026 (Item 2.02: Results of Operations and Financial Condition).
• Reporting period: Year ended December 31, 2025.
• Press release attached as Exhibit 99.1 (also referenced in Item 9.01).
• The Form 8-K notes, per General Instruction B.2 of Form 8-K, that the information (including Exhibit 99.1) is not deemed “filed” for purposes of Section 18 of the Exchange Act and is not automatically incorporated by reference into other filings.

Why It Matters

• This 8-K is the company’s formal disclosure that it has released its 2025 annual financial results; investors should review the attached press release (Exhibit 99.1) for the company’s reported earnings, revenue, and other key metrics.
• Because the item is an earnings/financial-results disclosure, it may affect TYRA’s stock price and analyst outlook once the figures are reviewed; for audited and more detailed financial statements, watch for the company’s subsequent periodic filings (e.g., Form 10-K).